Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

Alder Biopharmaceuticals, Inc. (ALDR) Promises to Relieve Migraine Misery with Leading Drug Candidate ALD403

A research report (http://dtn.fm/w6uT3) issued earlier this week by Aegis Capital Corp. shows that Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR) has lived up to its promise since 2004, when it received startup funding from the Army under the Small Business Technology Transfer (STTR) program. Since then the company has been working on the development of new […]

FTE Network (FTNW) – A Unique Opportunity for Explosive Growth

The expansion in data usage and communications has continued to inflate beyond all predictions, with networks rapidly being pushed far beyond originally anticipated requirements. The unparalleled growth is expected to continue as developing technologies challenge existing capabilities, creating an unprecedented demand for improved network infrastructures and associated services. Florida-based FTE Networks (OTCQX: FTNW) has grown […]

Moxian, Inc. (MOXC) – Facilitating Stronger Customer Relationships

Keeping and cultivating satisfied customers is clearly a critical aspect of any company’s success. Building and maintaining strong customer relationships is key, requiring businesses to not only stay in touch with customers, but also to effectively deal with any customer service issues. The most successful businesses have been known to build the most impressive records […]

Aerie Pharmaceuticals (AERI) Eyeing Innovative Glaucoma and Ocular Hypertension Therapies

Aerie Pharmaceuticals. Inc. (NASDAQ: AERI) is a publicly traded clinical stage pharmaceutical company focusing on the discovery of innovative treatments for glaucoma and other eye ailments. Its leading product candidates, Rhopressa™ and Roclatan™, are believed to be effective for most glaucoma patients, based on clinical trials results, and are currently in different stages of development […]

 

From Our Blog

BluSky AI Inc. (BSAI) Outlines Strategy to Tackle GPU Bottlenecks with Modular Distributed Neocloud Infrastructure

April 8, 2026

BluSky AI (OTC: BSAI) is strategically positioning itself at the forefront of a major shift in artificial intelligence infrastructure, where flexibility and predictable access to compute resources are becoming mission critical. With AI workloads increasing at unprecedented rates, organizations are changing their outlook on traditional hyperscale cloud providers and finding alternatives that reduce vendor lock-in, […]

Rotate your device 90° to view site.